Lymphoma – NCI-03-C-0304
Dr. Wyndham H. Wilson
Principal Investigator
NCI is currently conducting the following trial for patients with lymphoma. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Wilson and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
This is a pilot, dose-escalation study of alemtuzumab.
- Patients receive alemtuzumab IV over 12 hours on day 1 and EPOCH chemotherapy comprising etoposide IV, doxorubicin IV, and vincristine IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 15 minutes on day 5; and oral prednisone twice daily on days 0-5
- Patients also receive filgrastim subcutaneously starting on day 6
- Treatment repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity
- Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter
Why is this trial important?
The general purpose of this study is to develop treatments for lymphoma that are more effective than existing therapies. The experimental part of this treatment program is to test whether giving alemtuzumab in combination with continuous infusion EPOCH chemotherapy with filgrastim is safe and if it improves the outcome of therapy of your child's lymphoma.
Back to Top
